NovaBridge Biosciences ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.94next fiscal year
Monitoring Framework
Key Performance Indicators
Objective Response Rate (ORR) for Givastomig in 1L Gastric Cancer Annually77.0%Target: Maintain high efficacy in registrational Phase 3 trial
Median Progression-Free Survival (mPFS) for Givastomig (8 mg/kg cohort) Annually16.9Target: Exceed standard of care in Phase 3 trials
Cash Runway (Years of Funding) Quarterly3.0Target: Fund operations and clinical milestones through 2028
Watch Items
- Initiation of Registrational Phase 3 Trial for GivastomigTrigger: Trial commencement delay beyond Q4 2026Action: Re-evaluate clinical timeline, operational execution, and cash burn projections.
- Phase 2b Trial Initiation for VIS-101 in Wet AMDTrigger: Delay in starting Phase 2b trial beyond H2 2026Action: Assess regulatory feedback and clinical trial site readiness.
- Remediation of Material Weaknesses in IT General ControlsTrigger: Continued disclosure of IT control weaknesses in future SEC filingsAction: Review Audit Committee oversight and Deloitte's independent audit findings.
Research as of 19 Jun 2026